Latest news and major announcements from our companies.
November 2024
Idorsia Enters Into Exclusive Negotiations for Global Rights to Aprocitentan
April 2024
Richelieu Hardware Completes Acquisitions of Olympic Forest, Rapid Start and Allegheny Plywood
Mars 2024
FDA Approves Idorsia’s TRYVIO, the First and Only Endothelin Receptor Antagonist for the Treatment of High Blood Pressure
February 2024
Gear Energy Ltd. Announces Completion of the Strategic Repositioning Process and Intention to Commence Normal Course Issuer Bid
December 2023
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
November 2023
Statement from Daily Journal Corporation Regarding the Passing of Charles T. Munger
September 2023
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
June 2023
Petrus Resources Announces Credit Facility Increase and Approval For Normal Course Issuer Bid
March 2023
Generation Bio and Moderna Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
January 2023
Richelieu Hardware Increased Sales by 25.2% in 2022 with Accelerated Growth in the United States of 42.2%
July 2022
Tessenderlo Group and Picanol Group Announce Intention to Simplify Group Structure and Combine Activities
February 2022
All Preferred Shares and Preference Units of Topicus.com Inc. Converted
January 2022
FDA Approves Idorsia’s QUVIVIQ for the Treatment of Adults with Insomnia
October 2021
Idorsia Announces the Results of MODIFY, a Phase 3 Study of Lucerastat in Fabry Disease
July 2021
Richelieu Hardware Records Strong Growth and Pursues Successful Acquisition Strategy
March 2021
FDA Approves Idorsia’s PONVORY to Treat Adults with Relapsing Forms of Multiple Sclerosis